A new oral drug called hedgehog inhibitor can improve the condition of people with advanced skin and brain cancers that can't be treated by current methods.

Hedgehog is one of the latest anticancer targets currently. This signaling molecule called hedgehog initiates growth processes during embryonic stages and childhood but it is stopped during adulthood. While it is not turned off, it promotes growth in cancer cells.

Some cancer types are specifically dependent on hedgehog. One of then is the basal cell carcinoma which is among the most common skin cancer in the U. S. This cancer can although be treated in its initial stages but metastatic disease has no standard treatment and becomes fatal very fast.

A study conducted on 33 patients with either inoperable metastatic or locally advanced basal cell carcinoma showed a remarkably high percentage of response. It was 55 percent and only four patients had continued the progression of the cancer over a course of 10 months.

There is evidence that this class of drugs may be helpful in many different types of cancers. Other companies too are working on hedgehog inhibitors.